Why Retail Investors Are Piling Into the SpaceX IPO Despite a Historic $2.1 Trillion Valuation

A CNBC segment that ran last week opened with a sentence you do not normally hear from a buyer. “It’s stupid. It’s unreasonable… The valuation is really, really aggressive, in my opinion,” said Marvin Jung, a regional director of operations in veterinary care. Then he told CNBC he had requested roughly 1,000 shares of SpaceX through Robinhood anyway. That gap, between what retail investors are saying and what they are doing, is the actual story of the IPO.

Why analysts call the $2.1 trillion price aggressive

SpaceX is now public at a $2.1 trillion valuation. A Morningstar analyst told CNBC the company has been “significantly overvalued” and that investors will likely find better prices later. The Connectivity segment, mostly Starlink, did $11.4 billion in 2025 revenue with $7.17 billion in segment adjusted EBITDA; revenue grew 49.8% year over year. That is a real business.

The AI segment, formed by the February 2026 acquisition of xAI, posted a 2025 loss from operations of $6.35 billion on $3.2 billion in revenue, with first-quarter 2026 AI capex alone of $7.7 billion. Mid-roadshow, SpaceX disclosed roughly $26 billion in new annual revenue from Anthropic and Google partnerships, which hardened conviction.

The retail archetypes lining up for shares

What makes this IPO unusual beyond size is the allocation. Per CNBC, 20% to 30% of shares are going to retail, well above the normal sliver. Three archetypes are showing up. The short-term pop chaser, hoping to flip day-one demand.

The cautious position-taker, capping exposure at around $10,000 or two shares, treating it as a small lottery-ticket position. And the long-term believer, like recent Cornell graduate Andrew Chen, who told CNBC he wants to “underwrite Elon’s ability to execute in this growing TAM” and called it a “once in a lifetime opportunity.”

The Musk premium and the AI infrastructure bet

Day trader Ross Cameron, founder of Warrior Trading, put the bull case in a line to CNBC. The IPO “would be overvalued if it didn’t include Elon Musk… because it includes Elon Musk… It doesn’t really make sense on paper, but this is the right market environment.” CNBC kept returning to the reframing that “SpaceX is not one business… it’s three businesses” across communications, launch, and AI infrastructure. Eric Jackson of The AI Investor Podcast said he would not buy on day one or even in the first month, citing the low float and pent-up demand bottleneck.

Admiration plus patience is the Morningstar posture too. The Musk premium is real, but so is the dilution risk if xAI keeps consuming cash faster than Starlink can throw it off. Retail buyers who treat the IPO as a venture-style bet rather than a public-market trade are the ones most likely to come out ahead, because the path from a $1.8 trillion entry price to a higher one almost certainly runs through several years of messy quarterly prints.

Where Rocket Lab fits into the trade

For investors who do not get an allocation, Rocket Lab (NASDAQ:RKLB | RKLB Price Prediction) has been the de facto SpaceX proxy. Q1 revenue hit $200.35 million, up 63.46% year over year, with backlog at a record $2.20 billion and CEO Peter Beck citing “access to more than $2 billion in liquidity” in the 8-K filed May 7, 2026. The Neutron medium-lift rocket will likely debut later in 2026. Reddit sees the stock as the cheaper executable version of the SpaceX trade.

The risk both stocks share is execution. SpaceX must turn xAI capex into AI revenue, Starship into a reliable workhorse, and Starlink growth into something durable enough to justify a software-like multiple. Rocket Lab has to land Neutron’s debut later in 2026, integrate three acquisitions without margin slippage, and convert that $2.2 billion backlog into recognized revenue on schedule. Retail investors who get SpaceX allocations should also keep an eye on the eventual lock-up expiration, when early shareholders sitting on enormous private-market gains finally get to sell. That is when the Morningstar “better prices later” thesis gets tested in public, and when the RKLB-as-proxy trade either gets validated or quietly unwinds.